The two exceptional researchers at Helmholtz Munich are committed to enhancing treatment options for diseases that urgently require innovative solutions. While Prof. Ulrike Protzer is on a mission to establish a therapeutic hepatitis B vaccine for an HBV cure, Dr. Kamyar Hadian is focused on revolutionizing the treatment of rheumatoid arthritis (RA). With their respective biomedical projects, they were able to impress the judges from among 31 strong applications submitted by research institutions across Bavaria.
Ulrike Protzer developed TherVacB, a promising therapeutic hepatitis B vaccine capable of reactivating antiviral immune responses and a promising solution to the global health challenge of chronic hepatitis B. Preclinical models have demonstrated its effectiveness, and initial clinical trials are set to begin soon. The m4 Award will play a vital role in facilitating the essential development stages required for the ultimate formulation of TherVacB, and preparations for the establishment of a spin-off company to drive further clinical development.
Kamyar Hadian's pioneering efforts are focused on the treatment of RA. His project has yielded first-in-class inhibitors that show promise in improving the outcome of RA treatment in preclinical models. With the support of the m4 Award, the project will optimize compounds and advance these toward clinical testing, potentially revolutionizing the treatment of rheumatoid arthritis.
The groundbreaking work of Ulrike Protzer and Kamyar Hadian holds immense promise in advancing the treatment of hepatitis B and RA, offering new solutions to patients in need of innovative therapies.
More information
Read the full press release BioM here.
Check out more about Prof. Ulrike Protzer at the Institute of Virology and about the Hadian Group at the Research Unit Signaling and Translation.
